1200-05-1 Usage
Description
4-Aminomethylphenylacetic acid, also known as 4-AMPA, is a chemical compound with the molecular formula C9H11NO2. It is an organic compound characterized by a phenylacetic acid backbone, featuring a primary amine and a carboxylic acid functional group. This versatile molecule serves as a key starting material in the synthesis of a variety of pharmaceuticals and has potential applications in the treatment of neurological disorders, as well as in the development of new antibiotics and antimicrobial agents.
Uses
Used in Pharmaceutical Synthesis:
4-AMINOMETHYLPHENYLACETIC ACID is used as a starting material for the synthesis of various pharmaceuticals, including non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines. Its presence in these medications is crucial for their therapeutic effects, such as reducing inflammation and alleviating allergic reactions.
Used in Neurological Disorder Treatment:
In the medical field, 4-AMINOMETHYLPHENYLACETIC ACID is studied for its potential applications in the treatment of neurological disorders. Its unique structure allows it to interact with specific biological targets, offering a promising avenue for the development of new therapies to address unmet medical needs.
Used in Antibiotic and Antimicrobial Agent Synthesis:
4-AMINOMETHYLPHENYLACETIC ACID is also identified as a potential precursor for the synthesis of new antibiotics and antimicrobial agents. Given the increasing prevalence of antibiotic resistance, the development of novel antimicrobial compounds is of critical importance, and 4-AMPA may play a significant role in this endeavor.
Used in Organic Compound Synthesis:
In the realm of organic chemistry, 4-AMINOMETHYLPHENYLACETIC ACID is utilized as a precursor for the synthesis of other organic compounds. Its functional groups enable a range of chemical reactions, making it a valuable building block for the creation of diverse chemical entities with potential applications across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1200-05-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,2,0 and 0 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1200-05:
(6*1)+(5*2)+(4*0)+(3*0)+(2*0)+(1*5)=21
21 % 10 = 1
So 1200-05-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H11NO2/c10-6-8-3-1-7(2-4-8)5-9(11)12/h1-4H,5-6,10H2,(H,11,12)
1200-05-1Relevant articles and documents
A new strategy applied to the synthesis of an α-helical bicyclic peptide constrained by two overlapping i, i+7 side-chain bridges of novel design
Yu, Chongxi,Taylor, John W.
, p. 1731 - 1734 (1996)
A conformationally constrained, bicyclic, 14-residue peptide containing two overlapping i, i+7 side-chain bridges has been synthesized. The design of the side-chain linkage, which is built around a p-substituted benzene ring for rigidity, and the solid-phase approach applied to the peptide synthesis, are both new. A Boc/Benzyl peptide chain assembly method was combined with Fmoc/OFm orthogonal side-chain deprotection and solid-phase cyclization to form the first side-chain lactam bridge. A 2-(2-pyridyl)ethyl group (2-Pet), activated by methylation with CH3I in DMF, was then used in combination with Fmoc to allow a second orthogonal side-chain deprotection and solid-phase cyclization to form the second bridge. The circular dichroism spectrum of the product indicates that it is highly helical.
HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS
-
Page/Page column 131, (2018/01/17)
The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.
CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
-
Page/Page column 68, (2014/06/11)
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.